Melanom: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab) in Advanced Solid Tumors advanced non-melanoma skin cancer

Stadium/Indikation inkl. Kurzinfo

Melanom – 1st line

Anti-PD1 + anti-lag3Stadium III oder IV
(Auch mukosales Melanom)

Kurztitel

BMS 224-020
NCT01968109

Offizieller Titel

A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab) in Advanced Solid Tumors advanced non-melanoma skin cancer